EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Macrolide and non-macrolide resistance after 36 months of mass azithromycin distribution in Burkina Faso: A cluster randomized trial

Catherine E Oldenburg iD, Boubacar Coulibaly, Ali Sié, Mamadou Ouattara, Mamadou Bountogo, Guillaume Compaoré, Dramane Kiemde, Adama Compaoré, Guillaume Zonou, Armin Hinterwirth iD, Lina Zhong, Cindi Chen und 9 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciag051 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Catherine E Oldenburg und 20 weiteren Autor:innen. Beteiligte Einrichtung: Francis I Proctor Foundation, University of California, SanFrancisco, CA, USA. Hauptthemen laut MEDLINE: Azithromycin, Anti-Bacterial Agents, Macrolides, Drug Resistance, Bacterial. Gefördert von: Bill and Melinda Gates Foundation, Pfizer, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biannual mass azithromycin distribution to children aged 1-59 months reduces all-cause child mortality but selects for antimicrobial resistance (AMR). The World Health Organization (WHO) recommends ongoing surveillance of AMR in the context of azithromycin distribution. We evaluated the impact of twice-yearly distribution of azithromycin compared to placebo on AMR in the gut of children in Burkina Faso.

Methods

The Community Health with Azithromycin Trial (CHAT) was a 1:1 cluster randomized placebo-controlled trial in Nouna District, Burkina Faso from 2019-2023. Communities were randomized in a 1:1 fashion to twice yearly azithromycin (20 mg/kg) or matching placebo. At 36 months, rectal swabs were collected from a random sample of 15 children per community in 48 communities participating in the trial and assessed for AMR genetic resistance determinants using next-generation DNA sequencing (DNA-seq). We assessed the fold-change in macrolide and non-macrolide resistance determinants between treatment groups after 36 months.

Results

483 samples from 41 communities were analyzed at 36 months. There was no evidence of a difference in macrolide resistance determinants in the azithromycin group compared to the placebo group (fold-change 1.21, 95% confidence interval, CI, 0.96 to 1.52, P=0.62). There was no evidence of a difference in non-macrolide resistance genes, for example, beta-lactam resistance was similar between treatment groups (fold-change 1.05, 95% CI 0.79 to 1.40, P=0.81).

Conclusions

In this setting in Burkina Faso, twice-yearly azithromycin distributions to children aged 1-59 months did not lead to statistically significant differences in macrolide or non-macrolide genetic resistance determinants at 36 months. Trial Registration ClinicalTrials.gov NCT03676764

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzithromycinAnti-Bacterial AgentsMacrolidesDrug Resistance, BacterialMass Drug AdministrationBacteriaHumansBurkina FasoChild, PreschoolInfantFemaleMale

Stichwörter der Autor:innen

antimicrobial resistanceazithromycinchild mortalitymass drug administration

Substanzen

AzithromycinAnti-Bacterial AgentsMacrolides

Autor:innen und Institutionen

  • Francis I Proctor Foundation, University of California, SanFrancisco, CA, USA.
  • Department of Epidemiology & Biostatistics, University of California, SanFrancisco, CA, USA.
  • Department of Ophthalmology, University of California, SanFrancisco, CA, USA.
  • Institute for Global Health Sciences, University of California, SanFrancisco, CA, USA.
  • Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

ORCID-Profile: Catherine E Oldenburg, Armin Hinterwirth, Thuy Doan

Förderung

  • Bill and Melinda Gates Foundation
  • Pfizer, Inc.

Zitieren

APA

Oldenburg, C. E., Coulibaly, B., Sié, A., Ouattara, M., Bountogo, M., Compaoré, G., Kiemde, D., Compaoré, A., Zonou, G., Hinterwirth, A., Zhong, L., Chen, C., Liu, Y., Yu, D., Abraham, T., Lebas, E., Hu, H., Hilde-Jones, M., Arnold, B. F., …, & Lietman, T. M. (2026). Macrolide and non-macrolide resistance after 36 months of mass azithromycin distribution in Burkina Faso: A cluster randomized trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag051

Vancouver

Oldenburg CE, Coulibaly B, Sié A, Ouattara M, Bountogo M, Compaoré G, et al. Macrolide and non-macrolide resistance after 36 months of mass azithromycin distribution in Burkina Faso: A cluster randomized trial. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag051

BibTeX
@article{Oldenburg2026,
  author = {Oldenburg, Catherine E and Coulibaly, Boubacar and Sié, Ali and Ouattara, Mamadou and Bountogo, Mamadou and Compaoré, Guillaume and Kiemde, Dramane and Compaoré, Adama and Zonou, Guillaume and Hinterwirth, Armin and Zhong, Lina and Chen, Cindi and Liu, YuHeng and Yu, Danny and Abraham, Thomas and Lebas, Elodie and Hu, Huiyu and Hilde-Jones, Milan and Arnold, Benjamin F and Doan, Thuy and Lietman, Thomas M},
  title = {Macrolide and non-macrolide resistance after 36 months of mass azithromycin distribution in Burkina Faso: A cluster randomized trial},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag051}
}
Kostenlos starten →